“The AI’s compute crunch favors alternatives like AMDs. Why? They’ve got a cost edge over NVIDIA.” – 01:58
Evelio Silvera, Co-Founder of Bull Street Media, to provide insights into the latest developments in the tech sector. They begin by discussing AMD’s recent announcement of a strategic partnership with OpenAI, which has led to AMD shares reaching an all-time high. Evelio explains that this multi-billion-dollar deal involves the supply of six gigawatts of MI450 chips, which will power OpenAI’s AI data centers starting in the second half of the following year. He emphasizes that this partnership positions AMD as a serious competitor to NVIDIA, particularly in the realm of AI applications, and suggests that savvy investors are recognizing the potential for significant revenue growth.
The conversation then shifts to the pharmaceutical sector, focusing on the White House’s unveiling of Trump Rx. This initiative aims to eliminate pharmacy middlemen and reduce drug costs through a most favored nation pricing model. Evelio shares his perspective on how this could transform drug pricing in America, noting that companies like Pfizer are already experiencing positive market reactions, with Pfizer’s stock rising 14% post-announcement. He discusses the potential for substantial savings for consumers and how this initiative could lead to a revolution in pharmaceutical distribution.
Finally, Remy and Evelio address the recent controversy surrounding Netflix, which saw its shares fall nearly 5% after Elon Musk called for a boycott of the streaming service. Evelio acknowledges the legitimacy of Musk’s concerns but also points out that Netflix’s fundamentals remain strong. He notes that despite the social media noise, Netflix has posted record revenue and is diversifying its offerings into gaming and live events, which could attract a more stable subscriber base.